{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:15:24Z","timestamp":1792181724564,"version":"4.4.0"},"reference-count":92,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The presentation and delivery of antigens are crucial for inducing immunity and, desirably, lifelong protection. Recombinant viral vectors\u2014proven safe and successful in veterinary vaccine applications\u2014are ideal shuttles to deliver foreign proteins to induce an immune response with protective antibody levels by mimicking natural infection. Some examples of viral vectors are adenoviruses, measles virus, or poxviruses. The required attributes to qualify as a vaccine vector are as follows: stable insertion of coding sequences into the genome, induction of a protective immune response, a proven safety record, and the potential for large-scale production. The need to develop new vaccines for infectious diseases, increase vaccine accessibility, reduce health costs, and simplify overloaded immunization schedules has driven the idea to combine antigens from the same or various pathogens. To protect effectively, some vaccines require multiple antigens of one pathogen or different pathogen serotypes\/serogroups in combination (multivalent or polyvalent vaccines). Future multivalent vaccine candidates are likely to be required for complex diseases like malaria and HIV. Other novel strategies propose an antigen combination of different pathogens to protect against several diseases at once (multidisease or multipathogen vaccines).<\/jats:p>","DOI":"10.1128\/cvi.00298-16","type":"journal-article","created":{"date-parts":[[2016,8,17]],"date-time":"2016-08-17T22:24:19Z","timestamp":1471472659000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":102,"title":["Multivalent and Multipathogen Viral Vector Vaccines"],"prefix":"10.1128","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4347-7525","authenticated-orcid":false,"given":"Katharina B.","family":"Lauer","sequence":"first","affiliation":[{"name":"University of Manchester, Institute of Inflammation and Repair, Manchester, United Kingdom"},{"name":"University of Cambridge, Department of Pathology, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[{"name":"University of Manchester, Institute of Inflammation and Repair, Manchester, United Kingdom"},{"name":"Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Blanchard","sequence":"additional","affiliation":[{"name":"University of Manchester, Institute of Inflammation and Repair, Manchester, United Kingdom"},{"name":"Consultant in Infectious Diseases and Tropical Medicine, Royal Liverpool Hospital, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f6061"},{"key":"e_1_3_2_3_2","volume-title":"NIH Curriculum Supplement Series","author":"National Institutes of Health","year":"2007","unstructured":"National Institutes of Health. 2007. Understanding emerging and re-emerging infectious diseases. Biological sciences curriculum study. NIH Curriculum Supplement Series. National Institutes of Health,Bethesda, MD."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv126"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1615"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70845-X"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2015.29"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis327"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-3519(99)80043-3"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1017\/S0950268800052535","article-title":"The development and use of a vaccinia-rabies recombinant oral vaccine for the control of wildlife rabies; a link between Jenner and Pasteur","volume":"116","author":"Pastoret P-P","year":"1996","unstructured":"Pastoret P-P BrochierB. 1996. The development and use of a vaccinia-rabies recombinant oral vaccine for the control of wildlife rabies; a link between Jenner and Pasteur. Epidemiol Infect116:235\u2013240.","journal-title":"Epidemiol Infect"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00486-7"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411627"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nm.3702","article-title":"Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge","volume":"20","author":"Stanley DA","year":"2014","unstructured":"Stanley DA HonkoANAsieduCTrefryJCLau-KilbyAWJohnsonJCHensleyLAmmendolaVAbbateAGrazioliFFouldsKEChengCWangLDonaldsonMMCollocaSFolgoriARoedererMNabelGJMascolaJNicosiaACorteseRKoupRASullivanNJ. 2014. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med20:1126\u20131129.","journal-title":"Nat Med"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00362-X"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2005.08.008"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2011.03.006"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.7774\/cevr.2013.2.2.97"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1089\/vim.2005.18.317"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.01.064"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-3-7091-0709-6_5","volume-title":"Development of novel vaccines","author":"Loessner H","year":"2012","unstructured":"Loessner H SchwantesAHamdorfMKomorULeschnerSWeissS. 2012. Employing live microbes for vaccine delivery, p 87\u2013124. Invon GabainAKladeC (ed), Development of novel vaccines. Skills, knowledge and translational technologies. Springer, New York, NY."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.01.061"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.24.12180"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.25.11553"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1517\/14712591003601944"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1995.tb00266.x"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1586\/erv.12.84"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.05.086"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)70043-5"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.08.101"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1566523213666131125095046","article-title":"Adenovirus vectors for gene therapy, vaccination and cancer gene therapy","volume":"13","author":"Wold WSM","year":"2013","unstructured":"Wold WSM TothK. 2013. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther13:421\u2013433.","journal-title":"Curr Gene Ther"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.3109\/08830185.2013.823420"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/COH.0b013e328363d3b7","article-title":"Nonreplicating vectors in HIV vaccines","volume":"8","author":"Johnson JA","year":"2013","unstructured":"Johnson JA BarouchDHBadenLR. 2013. Nonreplicating vectors in HIV vaccines. Curr Opin HIV AIDS8:412\u2013420.","journal-title":"Curr Opin HIV AIDS"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.80.6.2738-2746.2006"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0076-6879(02)46075-2"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1006\/mthe.2001.0478"},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1385\/1-59259-304-6:167","volume-title":"Viral vectors for gene therapy","author":"Rubinchik S","year":"2002","unstructured":"Rubinchik S WoraratanadharmJScheppJDongJ. 2002. Improving the transcriptional regulation of genes delivered by adenovirus vectors, p 167\u2013199. InMachidaCA (ed), Viral vectors for gene therapy. Humana Press,New York, NY."},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00431-07"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1258"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00467-09"},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1111\/1469-0691.12580","article-title":"Varicella vaccination: a laboured take-off","volume":"20","author":"Carrillo-Santisteve P","year":"2014","unstructured":"Carrillo-Santisteve P LopalcoPL. 2014. Varicella vaccination: a laboured take-off. Clin Microbiol Infect20(Suppl):S86\u2013S91.","journal-title":"Clin Microbiol Infect"},{"key":"e_1_3_2_41_2","first-page":"219439","article-title":"Recombinant varicella-zoster virus vaccines as platforms for expression of foreign antigens","volume":"2013","author":"Gray WL","year":"2013","unstructured":"Gray WL . 2013. Recombinant varicella-zoster virus vaccines as platforms for expression of foreign antigens. Adv Virol2013:219439.","journal-title":"Adv Virol"},{"key":"e_1_3_2_42_2","doi-asserted-by":"crossref","first-page":"A44","DOI":"10.1089\/aid.2014.5075.abstract","article-title":"Mechanisms of protection observed with varicella zoster virus as a vaccine vector in the SIV macaque model","volume":"30","author":"Perciani CT","year":"2014","unstructured":"Perciani CT WillerDOHaqKIwajomoOHChanJKPilonRAntonyJMSandstromPMacdonaldKS. 2014. Mechanisms of protection observed with varicella zoster virus as a vaccine vector in the SIV macaque model. AIDS Res Hum Retroviruses30(Suppl):A44\u2013A45.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/1348-0421.12087"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1086\/379775"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00919-06"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1997.8697"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1086\/314769"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(98)00010-3"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000066244.31769.83"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.15.6821-6831.2000"},{"key":"e_1_3_2_51_2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.4161\/hv.7.4.14422","article-title":"Application of attenuated coxsackievirus B3 as a viral vector system for vaccines and gene therapy","volume":"7","author":"Kim D-S","year":"2011","unstructured":"Kim D-S NamJ-H. 2011. Application of attenuated coxsackievirus B3 as a viral vector system for vaccines and gene therapy. Hum Vaccin7:410\u2013416.","journal-title":"Hum Vaccin"},{"key":"e_1_3_2_52_2","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1161\/01.CIR.90.1.330","article-title":"Acute myocarditis. Rapid diagnosis by PCR in children","volume":"90","author":"Martin AB","year":"1994","unstructured":"Martin AB WebberSFrickerFJJaffeRDemmlerGKearneyDZhangYHBodurthaJGelbBNiJ. 1994. Acute myocarditis. Rapid diagnosis by PCR in children. Circulation90:330\u2013339.","journal-title":"Circulation"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01317202"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01309769"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-1702(97)00059-2"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.10.4570-4578.2000"},{"key":"e_1_3_2_57_2","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1099\/0022-1317-73-6-1429","article-title":"Antipeptide antisera define neutralizing epitopes on the adenovirus hexon","volume":"73","author":"Toogood CI","year":"1992","unstructured":"Toogood CI CromptonJHayRT. 1992. Antipeptide antisera define neutralizing epitopes on the adenovirus hexon. J Gen Virol73:1429\u20131435.","journal-title":"J Gen Virol"},{"key":"e_1_3_2_58_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF01311113","article-title":"Partial deletion of the human host range gene in the attenuated vaccinia virus MVA","volume":"105","author":"Altenburger W","year":"1989","unstructured":"Altenburger W S\u00fcterC-PAltenburgerJ. 1989. Partial deletion of the human host range gene in the attenuated vaccinia virus MVA. Arch Virol105:15\u201327.","journal-title":"Arch Virol"},{"key":"e_1_3_2_59_2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1099\/0022-1317-72-5-1031","article-title":"Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence","volume":"72","author":"Meyer H","year":"1991","unstructured":"Meyer H SutterGMayrA. 1991. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol72:1031\u20131038.","journal-title":"J Gen Virol"},{"key":"e_1_3_2_60_2","first-page":"140","article-title":"Virulenz und immunogenit\u00e4teines modifizierten vaccinia-virus (Stamm MVA). immunit\u00e4tsforsch","volume":"144","author":"Hochstein-Mintzel V","year":"1972","unstructured":"Hochstein-Mintzel V HuberHCSticklH. 1972. Virulenz und immunogenit\u00e4teines modifizierten vaccinia-virus (Stamm MVA). immunit\u00e4tsforsch. Exp Klin Immunol144:140\u2013145.","journal-title":"Exp Klin Immunol"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01641272"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107316"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200111001-00007"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0100-879X2005000400004"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543770802587226"},{"key":"e_1_3_2_66_2","first-page":"479","volume-title":"Fundamental immunology","author":"Pickering PJ","year":"1999","unstructured":"Pickering PJ SiegelmanMH. 1999. Lymphoid tissues and organs, p 479\u2013532. InPaulWE (ed), Fundamental immunology,4th ed. Lippincott-Raven,Philadelphia, PA.","edition":"4"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1086\/322579"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2015.06.015"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02308-14"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2014.11.028"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.12.009"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12896-015-0121-4"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2005.07.001"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0044"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2010.02.005"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00740-09"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3836"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu579"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055571"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.06.073"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00154-1"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aab3920"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61117-5"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2006.05.033"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.6.4823-4828.1999"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.1.146-157.2004"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050397"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.01.057"},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.09.072"},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.1086\/426824"},{"key":"e_1_3_2_91_2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.virol.2014.01.002","article-title":"Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein","volume":"452","author":"Escriou N","year":"2014","unstructured":"Escriou N CallendretBLorinVCombredetCMarianneauPF\u00e9vrierMTangyF. 2014. Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein. Virology452\u2013453:32\u201341.","journal-title":"Virology"},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.01.057"},{"key":"e_1_3_2_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.07.073"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00298-16","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00298-16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T11:43:04Z","timestamp":1627558984000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00298-16"}},"subtitle":[],"editor":[{"given":"Christopher J.","family":"Papasian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1128\/CVI.00298-16"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00298-16","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"2017-01-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}